All-new AI tool lightens the workload for researchers studying COVID-19

Stepping outside the comfort zone of their normal daily focus—materials science—an unlikely team at Berkeley Lab has created a text-mining tool that may help scientists of all disciplines tame and tap the presently blinding blizzard of COVID-19 papers.

The NLP-powered tool scans and searches these papers, quickly highlighting connections it might take a human many hours to uncover.

The team is calling the tool COVIDScholar.

In an item published April 28 by the news division of the lab—more formally the Lawrence Berkeley National Laboratory—the team says its innovation arose out of a call to action issued by the White House in March.

Specifically, the executive branch’s Office of Science and Technology Policy asked AI experts for help developing new text- and data-mining techniques that might answer pressing questions about COVID-19.

Just a few weeks later, here’s materials scientist and engineer Gerbrand Ceder, PhD:

“On Google and other search engines people search for what they think is relevant. Our objective is to do information extraction so that people can find nonobvious information and relationships. That’s the whole idea of machine learning and natural language processing that will be applied on these datasets.”

To this project co-leader Kristin Persson, PhD, adds that every field of scientific inquiry produces mountains of scholarly material. However, the scholarly verbosity accumulating in the COVID-19 storm is especially daunting.

“There’s no doubt we can’t keep up with the literature, as scientists,” Persson says. “We need help to find the relevant papers quickly and to build correlations between papers that may not, on the surface, look like they’re talking about the same thing.”

A third source quoted in Berkeley’s own coverage, graduate student John Dagdelen, says the accessibility of the millions of articles in the Google Scholar database is powerful in its own right.  

“However, when you search for ‘spleen’ or ‘spleen damage’—and there’s research coming out now that the spleen may be attacked by the virus—you’ll get 100,000 papers on spleens, but they’re not really relevant to what you need for COVID-19. We have the largest single-topic literature collection on COVID-19.”

Click here for the rest of the story from Berkeley Lab.

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.